Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Related Keywords

United States ,Spain ,Switzerland ,Barcelona ,Comunidad Autonoma De Cataluna ,America ,Kevin Garey ,Eugenie Basseres ,Davidp Luci ,Society Or Healthcare Epidemiology Of America ,Exchange Commission ,Research Scientist ,Company Scientific Advisory Board ,Prnewswire Acurx Pharmaceuticals Inc ,Company Ph ,Global European Society Of Clinical Microbiology ,Trial Oversight Committee ,Drug Administration ,Acurx Pharmaceuticals ,University Of Houston College Pharmacy ,Nasdaq ,Data Monitoring Committee ,Acurx Pharmaceuticals Inc ,Exchange Commission On Form ,Infectious Diseases Society Of America ,European Society Of Clinical Microbiology ,European Society ,Clinical Microbiology ,Infectious Diseases ,Houston College ,Principal Investigator ,Acurx Scientific Advisory Board ,Double Blind Study ,Ibezapolstat Compared ,Executive Committee ,Ibezapolstat Phase ,Scientific Advisory Board ,Clinical Cure ,Modified Intent ,Treat Population ,Per Protocol Population ,Prescribing Information ,Independent Data Monitoring Committee ,Fast Track Designated ,Gram Positive Selective Spectrum ,Qualified Infectious Disease Product ,Generating New Antibiotic Incentives Now ,Clinical Practice Guidelines ,Infectious Diseases Society ,Healthcare Epidemiology ,New England Journal ,Bile Acid ,Private Securities Litigation Reform Act ,